![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Legend Biotech Corporation | NASDAQ:LEGN | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 58.93 | 58.00 | 60.00 | 0 | 09:43:39 |
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended June 30, 2020.
“Legend Biotech continues to execute on our corporate strategy, advancing the development of our lead product candidate, ciltacabtagene autoleucel (cilta-cel), in collaboration with Janssen Biotech, Inc. as well as our other pipeline programs,” said Frank Zhang, Ph.D., Chief Executive Officer and Chairman of the Board of Legend Biotech. “We look forward to presenting data from the CARTITUDE-1 study at a major medical conference in the second half of 2020.”
Second Quarter 2020 & Recent Highlights
Key Upcoming Milestones
The extent to which the COVID-19 may impact our business and clinical trials is highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak and social distancing regulations, travel restrictions, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
Financial Results for the Quarter Ended June 30, 2020
Cash and Cash Equivalents:
As of June 30, 2020, Legend Biotech had approximately $562.4 million of cash and cash equivalents and approximately $75.6 million in time deposits.
Revenue
Revenue for the three months ended June 30, 2020 was $11.6 million compared to $10.1 million for the three months ended June 30, 2019. This increase of $1.5 million was primarily due to additional milestone payments from Janssen Biotech, Inc. that were achieved in late 2019, which resulted in additional consideration being allocated to steering committee service for the three month ended June 30, 2020. Revenue for the three months ended June 30, 2020 and June 30, 2019 consisted of recognition of upfront and milestone payments allocated to steering committee service pursuant to the license and collaboration agreement with Janssen Biotech, Inc. Legend Biotech has not generated any revenue from product sales to date.
Research and Development Expenses
Research and development expenses for the three months ended June 30, 2020 were $53.6 million compared to $32.6 million for the three months ended June 30, 2019. This increase of $21.0 million was primarily due to a higher number of clinical trials, a higher number of patients enrolled in those trials and a higher number of research and development product candidates in the three months ended June 30, 2020.
Administrative Expenses
Administrative expenses for the three months ended June 30, 2020 were $4.5 million compared to $1.6 million for the three months ended June 30, 2019. This increase of $2.9 million was primarily due to Legend Biotech’s expansion of supporting administrative functions to aid continued research and development activities.
Selling and Distribution Expenses
Selling and distribution expenses for the three months ended June 30, 2020 were $9.6 million compared to $5.0 million for the three months ended June 30, 2019. This increase of $4.6 million was primarily due to increased costs associated with commercial preparation activities for cilta-cel.
Other Income and Gains
Other income and gains for the three months ended June 30, 2020 was $1.3 million compared to $1.2 million for the three months ended June 30, 2019.
Fair Value Loss of Convertible Redeemable Preferred Shares
For the three months ended June 30, 2020, Legend Biotech reported a one-time non-cash charge of $80.0 million caused by changes of fair value of Series A convertible redeemable preferred shares (Series A Preferred Shares). Upon listing on the Nasdaq Global Market, all outstanding Series A Preferred Shares were converted into ordinary shares of Legend Biotech and all accrued but unpaid dividends were settled in the form of ordinary shares of Legend Biotech.
Loss for the Period
For the three months ended June 30, 2020, net loss was $134.9 million, or $0.63 per share, compared to a net loss of $28.8 million, or $0.14 per share, for the three months ended June 30, 2019.
About Legend Biotech
Legend Biotech is a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Our team of over 700 employees across the United States, China and Europe, along with our differentiated technology, global development, and manufacturing strategies and expertise, provide us with the strong potential to discover, develop, and manufacture best-in-class cell therapies for patients in need.
We are engaged in a strategic collaboration with Janssen Biotech, Inc. to develop and commercialize our lead product candidate, ciltacabtagene autoleucel, an investigational BCMA-targeted CAR-T cell therapy for patients living with multiple myeloma. This candidate is currently being studied in registrational clinical trials.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s strategies and objectives; the anticipated timing of, and ability to progress, clinical trials; the ability to make, and the timing of, regulatory submissions in the United States, Europe and Asia, including the BLA filing for cilta-cel to the U.S. FDA, the submission of a marketing authorization application for cilta-cel to the EMA, and the submission of an IND LB1901 in relapsed or refractory TCL; the ability to generate, analyze and present data from clinical trials; patient enrollment; and the potential benefits of our product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the factors discussed in the “Risk Factors” section of the prospectus filed with the Securities and Exchange Commission on June 8, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Readers should not rely upon the information on this page as current or accurate after its publication date.
LEGEND BIOTECH CORPORATION UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019
Three months ended June 30
Six months ended June 30
(in thousands, US$, except share and per share data)
2020 (unaudited)
2019 (unaudited)
2020 (unaudited)
2019 (unaudited)
REVENUE
11,600
10,087
23,146
20,140
Other income and gains
1,265
1,221
3,796
4,073
Research and development expenses
(53,567)
(32,640)
(101,570)
(53,929)
Administrative expenses
(4,508)
(1,607)
(7,938)
(2,712)
Selling and distribution expenses
(9,557)
(5,030)
(16,102)
(7,786)
Other expenses
(37)
(478)
(82)
(625)
Fair value loss of convertible redeemable preferred shares
(79,984)
—
(79,984)
—
Finance costs
(88)
(19)
(4,079)
(57)
LOSS BEFORE TAX
(134,876)
(28,466)
(182,813)
(40,896)
Income tax (expense)/credit
—
(336)
3,709
(336)
LOSS FOR THE PERIOD
(134,876)
(28,802)
(179,104)
(41,232)
Attributable to:
Equity holders of the parent
(134,876)
(28,802)
(179,104)
(41,232)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Ordinary shares—basic
(0.63)
(0.14)
(0.86)
(0.21)
Ordinary shares—diluted
(0.63)
(0.14)
(0.86)
(0.21)
Ordinary shares used in loss per share computation:
Ordinary shares—basic
215,551,887
200,000,000
207,775,944
200,000,000
Ordinary shares—diluted
215,551,887
200,000,000
207,775,944
200,000,000
LEGEND BIOTECH CORPORATION UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AS AT JUNE 30, 2020 AND DECEMBER 31, 2019
June 30, 2020 (Unaudited)
December 31, 2019
(in thousands, US$)
NON-CURRENT ASSETS
Property, plant and equipment
88,589
70,079
Advance payments for property, plant and equipment
2,121
665
Right-of-use assets
7,786
9,348
Intangible assets
978
519
Total non-current assets
99,474
80,611
CURRENT ASSETS
Inventories
1,668
1,157
Trade receivables
—
29,991
Prepayments, other receivables and other assets
33,517
16,777
Pledged short-term deposits
256
256
Time deposits
75,559
75,559
Cash and cash equivalents
562,391
83,364
Total current assets
673,391
207,104
Total assets
772,865
287,715
CURRENT LIABILITIES
Trade and notes payables
6,976
9,586
Other payables and accruals
60,429
70,854
Lease liabilities
1,314
1,027
Contract liabilities
46,312
46,294
Total current liabilities
115,031
127,761
NON-CURRENT LIABILITIES
Contract liabilities
254,714
277,765
Lease liabilities
2,119
5,058
Total non-current liabilities
256,833
282,823
Total liabilities
371,864
410,584
EQUITY
Share capital
26
20
Reserves/(deficits)
400,975
(122,889)
Total ordinary shareholders’ equity/(deficit)
401,001
(122,869)
Total equity/(deficit)
401,001
(122,869)
Total liabilities and equity
772,865
287,715
LEGEND BIOTECH CORPORATION UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2020 AND 2019
Three months ended June 30
Six months ended
June 30
(in thousands, US$)
2020 (Unaudited)
2019 (Unaudited)
2020 (Unaudited)
2019 (Unaudited)
LOSS BEFORE TAX
(134,876)
(28,466)
(182,813)
(40,896)
CASH FLOWS USED IN OPERATING ACTIVITIES
(56,885)
(38,766)
(102,681)
(43,025)
CASH FLOWS USED IN INVESTING ACTIVITIES
(9,212)
(36,031)
(26,711)
(150,909)
CASH FLOWS FROM/(USED IN) FINANCING ACTIVITIES
459,803
(7,177)
608,558
21,500
NET INCREASE/(DECREASE) IN CASH AND CASH EQUIVALENTS
393,706
(81,974)
479,166
(172,434)
Effect of foreign exchange rate changes, net
(112)
(16)
(139)
(11)
Cash and cash equivalents at beginning of the period
168,797
119,711
83,364
210,166
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD.
562,391
37,721
562,391
37,721
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances
638,206
149,032
638,206
149,032
Less: Pledged short-term deposits
256
250
256
250
Time deposits
75,559
111,061
75,559
111,061
Cash and cash equivalents as stated in the statement of financial position
562,391
37,721
562,391
37,721
Cash and cash equivalents as stated in the statement of cash flows
562,391
37,721
562,391
37,721
1tacabtagene autoleucel (cilta-cel) refers to both JNJ-4528 (the identifier for the investigational product being studied outside of China) and LCAR-B38M CAR-T cell (the identifier for the investigational product being studied in China), both of which identify the same CAR-T cell therapy.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200828005366/en/
Media and Investor Relations: Jessie Yeung, Head of Corporate Finance and Investor Relations, Legend Biotech jessie.yeung@legendbiotech.com or investor@legendbiotech.com
1 Year Legend Biotech Chart |
1 Month Legend Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions